My writing has been cited for its clarity, scientific accuracy, and felicity of expression and has appeared in such publications as The New England Journal of Medicine, JAMA, Neurology, American Journal of Cardiology, Ophthalmology, Europace, Drugs, Journal of Neuroimaging, Annals of Pharmacotherapy, Current Medicine Research Opinions, Journal of Clinical Psychopharmacology, and Current Neuropharmacology.

Primary fields of expertise: cardiology, atrial fibrillation, metabolic diseases, diabetes, neurology, Alzheimer’s disease, multiple sclerosis, oncology, psychiatry, depression, anxiety disorders, ophthalmology, macular degeneration, HIV/AIDS, radiology, gastroenterology, irritable bowel disease, peptic ulcer, infectious diseases.

Selected Bibliography*

• Original Research Papers
  • Beasley DG, Meyer TA. Characterization of the UVA protection provided by avobenzone, zinc oxide, and titanium dioxide in broad-spectrum sunscreen products. Am J Clin Dermatol. 2010;11:413-21.
  • Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;141:638-645.
  • Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:14-22.
  • Ponec D, Jaff MR, SwischukJ, Feiring A, Laird J, Mehra M et al. The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty. J Vasc Interv Radiol. 2004;15:911-18.
  • Weissman NJ, Wilensky RL, Tanguay J-F et al. Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population. Am J Cardiol. 2001;88:248-52.
  • Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol. 1993;13(suppl 2):18s-22s.
• Basic Science Reviews
  • Yong VW, Marks S. The interplay between the immune and central nervous systems in neuronal injury. Neurology. 2010;74 (suppl 1):S9-S16.
  • Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74(suppl 1):S17-S24.
• Health Economics and Outcomes Research Papers
  • Kutikova L, Bowman L, Chang S et al. Non-hodgkin’s lymphoma: economic burden and the cost of treatment failure in the United States. Leuk Lymphoma. 2006;47:1535-44.
  • Kutikova L, Bowman L, Change S et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50:143-154.
• Consensus Conference Reports
  • Blumberg J, Heber D. Multivitamins and public health: exploring the evidence. Consensus document sponsored by Friedman School of Nutrition at Tufts University and the UCLA Center for Human Nutrition. 2004.
  • Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH et al. Diagnosis and treatment of Alzheimer’s disease and related disorders. JAMA. 1997;278:1363-71.
• Clinical Reviews
  • Leist TP, Marks S. Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics. Neurology. 2010;74(suppl 1):S54-S61.
  • Schwartz J, Roth T. Neurophysiology of sleep and wakefulness: Basic science and clinical implications. Curr Neuropharmacol. 2008;6:367-78.
  • McWhirter D, Bae C, Budur K. The assessment, diagnosis, and treatment of excessive sleepiness: Practical implications for the psychiatrist. Psychiatry. 2007;5:25-36.
  • Arnold DL. Evidence for neuroprotection and remyelination using imaging techniques. Neurology. 2007;68 (Suppl 3):s83-91.
  • Khan OA. Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology. 2007;68 (Suppl 3):s64-72
  • Zivadinov R. Can imaging techniques measure neuroprotection and remyelination? Neurology. 2007;68 (Suppl 3):s72-83.
  • Van Gelder IC, Hemels ME. The progressive nature of atrial fibrillation: new approaches to the restoration and maintenance of sinus rhythm. Europace. 2006 Nov;8(11):943-9.
  • Thase ME. Differentiating bipolar from unipolar depression: issues in diagnosis and treatment. Har Rev Psychiatry. 2005;13:257-71.
  • Bakshi R. Magnetic resonance imaging advances in multiple sclerosis. J Neuroimaging. 2005;15:5s-9s.
  • Bakshi R, Dandamudi VSR, Neema M, Chitadeep D, Bermel R. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis. J Neuroimaging. 2005;15:30s-45s.
  • Crijns HJGM. Rate versus rhythm: what the trials really say. Drugs. 2005;65:1651-67.
  • Weissman NJ. Contrast echocardiography: Fulfilling the promise? J Noninvas Cardiol. 1999;140:116-23.
  • Small GW. Differential diagnosis and early detection of dementia. Am J Geriatr Psychiatry. 1998;6:s26-s33.
  • Bone RC. Bronchial asthma: diagnostic and treatment issues. Hosp Practice. 1993;28:45-52.
  • Stokes PE. Current issues in the treatment of major depression. J Clin Psychopharmacol. 1993;13(suppl 2):2s-9s.
• Mechanistic Analyses
  • Campbell RK. Rationale for dipeptidyl dipeptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes. Ann Pharmacother. 2007;41:51-60.
  • Pratley R, Salsali A. Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23:919-31.
  • Henderson WR. New modalities for the psychopharmacology of asthma: leukotriene inhibitors and antagonists. Immunol Allergy Clin North Am. 1996;16:797-808.
  • Nemeroff CB. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol.1993;(suppl 2):10s-17s.
  • Duboff EA. Long-term treatment of major depressive disorder with paroxetine. J Clin Psychopharmacol. 1993;(suppl 2):28s-33s.
• Continuing Medical Education Programs: Monographs and Slide Sets
  • SCIX: The Science of Clinical Innovation and Excellence — a 3-day education program for the medical affairs and drug development departments. Bristol-Myers Squibb.
  • Costello K. Timely Topics in MS Nursing: New Insights into MS Immunpathology — Implications for Treatment and Long-Term Outcomes. Sponsored by Teva Neuroscience.
  • Zacharski LR, Mousa S, Ornstein DL. Low-molecular-weight heparins in cancer: thrombosis and beyond. 2003-4. Pharmion Inc.
  • Drossman DA. Quality of life in irritable bowel syndrome. 2003-4. Novartis Pharmaceuticals Corporation.
  • Drossman DA, Clouse RE, Chey WD, Koch KL, Lembo T, Locke GR et al. Irritable bowel syndrome: new visions. 1999-2000. American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy.
  • Tariot PN, Jeste DV, Schneider LS, Cummings JL, Devanand DP, Alexopoulos GS et al. Behavior disturbances in dementia. 1999-2000. American Association for Geriatric Psychiatry.
  • Small GW, Rabins PV. Diagnosis and treatment of Alzheimer’s disease and related disorders: what the clinician needs to know. 1998-9. American Association for Geriatric Psychiatry.
  • Schiff DR, Maddrey WC, Keeffe EB, Davis GL, Hoofnagle JH, Lindsay KL et al. An epidemic in the making? New approaches to the prevention, diagnosis, and treatment of viral hepatitis. 1997-8. American Gastroenterological Association and the American Liver Foundation.
• Monographs, Reports, Articles, and Speeches
  • Marks S. Adult Immunization: The Need for Enhanced Utilization. Available here.
  • Yankus W, Marks S. Counterfeit Drugs: Coming to a Pharmacy Near You (2nd Ed.) American Council on Science and Health. Available here.
  • Marks S. The Pharmaceutical Treatment of Obesity: New Pathways, New Approaches. American Council on Science and Health. Available here.
  • Marks S. Docs, Not Drug Companies, Call the Shots. Op-ed available here.
  • Marks S. Internet Drugs? Be careful. News feature available here.
  • DES Bulletin and PCI Controversies. E-blast and newsletter. Highlights from the DES Safety Summit, TCT annual meeting. 2007.
  • Marks S. Weighing benefits and risks in pharmaceutical use: a consumer’s guide. Available at http://www.acsh.org.
  • PARTNERS – clinical trial road map. Bristol-Myers Squibb.
  • Marks S. The blind alley of financial conflicts of interest. Available at http://www.acsh.org. Accessed December 2004.
  • Neura Onsite. Daily news reports from the 2004 annual meetings of the American Academy of Neurology, the European Neurological Society, and the Movement Disorders Society. Teva Neuroscience.
  • Kaplan SA. BPH management: new paradigms, new approaches. Urology Times. November 1, 2003.
  • Hope through discovery. Sanofi-Synthelabo Research and Development. Annual report. 2003.
  • Conquering heart disease: 50 years of progress in patient care. American College of Cardiology. 50th Anniversary Report. 1999.
  • Marks S. The Marketplace: a monthly column on the pharmaceutical business. Journal of the International Association of Physicians in AIDS Care. 1994-5.
  • Marks S. Special report: The Clinton plan and managed care. MD. 1994;38:19-24.
  • Biotechnology in a changing world. Amgen Research. Annual report. 1993 and 1991
  • Friedman D. Preventing strokes: true health care reform. Medical World News. December 1993.
  • Intellectual property: why America is losing the trade war. Speech by Amgen CEO Gordon Binder. 1992.
  • Snell P. rHuEPO: sports newest threat. Ortho Rev. 1992;21:113-4.
  • Scott WC. The abuse of erythropoietin to enhance athletic performance. JAMA. 1990;264:1660
  • Maier R. “New math” teaches lessons of reducing costs of care. Modern Healthcare. October 27, 1989.
  • Watson AJS. Is improved rehabilitation possible with EPO? Nephrology News and Issues. June 1989.

*documents available upon request